NCT03684967 is a Phase 2 clinical trial of Fruquintinib in Lung Cancer, sponsored by Hutchison Medipharma Limited.

Who is sponsoring NCT03684967?

NCT03684967 is sponsored by Hutchison Medipharma Limited.

What drugs are being tested in NCT03684967?

Interventions in NCT03684967: Fruquintinib.

What condition does NCT03684967 study?

NCT03684967 studies Lung Cancer.

Is NCT03684967 still recruiting?

NCT03684967 is currently withdrawn. Last updated 19 November 2019.

Last reviewed 2019-11-19 · How we verify

NCT03684967

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Withdrawn Phase 2 Last updated 19 November 2019

What this trial tests

Phase 2 trial testing Fruquintinib in Lung Cancer. Withdrawn.

Timeline

8 May 2018

Primary endpoint
6 September 2019

6 September 2019

Quick facts

Lead sponsor	Hutchison Medipharma Limited
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	8 May 2018
Primary completion	6 September 2019
Estimated completion	6 September 2019
Sites	1 location across China

Drugs / interventions tested

Fruquintinib — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Hutchison Medipharma Limited — full company profile →

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fruquintinib administered at 4 mg once daily in cycle 1 and 5 mg once daily in followed cycles (3 weeks on and 1 week off, 4 weeks as 1 cycle) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with advanced NSCLC in phase II study. This study is aimed to evaluate the efficacy and safety of Fruquintinib in the treatment of high risk patients with advanced NSCLC who is \> 75 years, or Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 2, or without systemic chemotherapy, or with at least three lines systemic chemotherapies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

AIMedGraph: a comprehensive multi-relational knowledge graph for precision medicine.
Quan X, Cai W, Xi C, Wang C, et al · · 2023 · cited 7× · PMID 36856726 · DOI 10.1093/database/baad006

Verify or expand the search:

Other trials of Fruquintinib

Trials testing the same drug.

NCT07510932 — Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients · Phase 2 · not yet recruiting
NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
NCT07124858 — Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metast · NA · not yet recruiting
NCT07446465 — FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectab · Phase 4 · not yet recruiting
NCT07235293 — A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorecta · Phase 2 · recruiting

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Hutchison Medipharma Limited trials

Trials by the same sponsor.

NCT05509699 — Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer · Phase 2 · completed
NCT05318820 — A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manuf · EARLY_PHASE1 · completed
NCT05277454 — Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT · Phase 1 · unknown
NCT05015608 — Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification · Phase 3 · active not recruiting
NCT05029635 — Phase III Study on HMPL-523 for Treatment of ITP · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03684967 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hutchison Medipharma Limited
Last refreshed: 19 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03684967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing